Intellia Therapeutics (NTLA) is Upgraded by Jefferies to Buy

Intellia Therapeutics (NTLA) was Upgraded by Jefferies to ” Buy”. Earlier the firm had a rating of “Hold ” on the company shares. Jefferies advised their investors in a research report released on Aug 5, 2016.

Many Wall Street Analysts have commented on Intellia Therapeutics. Credit Suisse Initiated Intellia Therapeutics on May 31, 2016 to “Outperform”, Price Target of the shares are set at $39.Jefferies Initiated Intellia Therapeutics on May 31, 2016 to “Hold”, Price Target of the shares are set at $33.Wedbush Initiated Intellia Therapeutics on May 31, 2016 to “Outperform”, Price Target of the shares are set at $38.

Intellia Therapeutics

Leave a Reply

Intellia Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intellia Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.